RE:RE:Ph 1b patients #5 and #6 still cancer free after 2 yearsInfinity ... Quite possible that it's rather TLT that asked big pharmas to come back later when more Ph. 2 data is out. When you have something you know everyone will want, that's the position you usually take. You wait till the data is undisputable so you can have the best position when negociations come. And I saw this for a biotech that was bought for 30B$US in 2017:
"It's the right deal, at the right time with the right partners." The agreement ends several months of back-and-forth between the two drugmakers, which included J&J at one point walking away. That's when Actelion struck up talks with Sanofi. The founders, a couple, turned down every offers until they were ready to sell. Then, they opened up the negociations with 2 big pharmas (Sanofi and J&J). Looks like we have the same mentality here.
Roger knew even before the start of the phase 1 that he would go all alone in the Ph. 2. That's because he knew he had something unique. So far, he's been right. You can't blame him for having the right vision and mastering the key elements that will maximize the shareholders value when the right time comes.
April 2014:
Theralase CEO Roger White talks to Cantech Letter How does mice data translate to human data?
If you are investigating monoclonal antibodies, then I believe that mouse data would not translate well to human data as different mammalian cells (mouse versus human, for example) would have different markers on the cancer cell surface. However, if you are investigating small molecules that enter a cancer cell, then I believe that mouse data would translate extremely well to human data in the sense that all eurkaryotes (mammalian cells) have almost identical cells and associated organelles, except for minor differences in DNA coding attributable to variations in species.Therefore, the strong and successful pre-clinical data collected by Theralase on mouse data should translate extremely well to human clinical testing.